ICU · Infectious Diseases
Severe falciparum malaria in the ICU
Also known as Severe malaria · Falciparum malaria · Cerebral malaria · Artesunate
Severe falciparum malaria is a medical emergency caused by Plasmodium falciparum, which accounts for most global malaria mortality. WHO criteria for severe malaria: cerebral malaria (impaired consciousness, unrousable coma, seizures), lactic acidosis, hypoglycaemia, severe malarial anaemia, renal impairment and AKI, ARDS or pulmonary oedema, jaundice and liver dysfunction, thrombocytopenia and DIC, hyperparasitaemia (over 4 per cent in adults with imported malaria), haemoglobinuria (blackwater fever), shock (algid malaria, often with concomitant bacterial infection). Diagnosis: thick film (screening), thin film (species ID + parasitaemia quantification), rapid diagnostic test (antigen, an important addition to microscopy), PCR (reference standard). Treatment: IV artesunate 2.4 mg/kg at 0, 12, 24 h then daily — 34.7% mortality reduction vs quinine in Asia (SEAQUAMAT), 22.5% in African children (AQUAMAT). No routine exchange transfusion, steroids, mannitol, or anticonvulsant prophylaxis. Monitor for post-artemisinin delayed haemolysis (7-30 days, weekly Hb checks for a month).
Practise this topic
On this page
Study tools
Your progress
Saved on this device.
Target exams
Red flags
- IV artesunate is FIRST-LINE — superior to quinine (SEAQUAMAT trial, 35% mortality reduction). Give immediately, do NOT wait for species confirmation
- Hypoglycaemia is common and recurrent — monitor glucose hourly (quinine worsens it via hyperinsulinaemia; artesunate less so but still occurs)
- Cerebral malaria: do NOT routinely give steroids, mannitol, or anticonvulsant prophylaxis (no proven benefit, may be harmful)
- Exchange transfusion is NOT routinely recommended — meta-analysis and observational data show no survival benefit
- Post-artemisinin delayed haemolysis (PADH) occurs 1-3 weeks after artesunate — monitor Hb after discharge
- Any febrile returning traveller from an endemic area has malaria until proven otherwise — send blood films STAT
- Artesunate clears parasites faster than quinine — persistently high parasitaemia after treatment suggests resistance or an alternative diagnosis
Meet the patient
A 34-year-old non-immune man returns from three weeks in Ghana, having taken incomplete prophylaxis. He presents twelve days after return with fever, confusion, and two generalised seizures. GCS 9, temperature 39.2, glucose 2.0 mmol per litre. Thick film shows heavy parasitaemia at 8 per cent, bilirubin 85, creatinine 220, lactate 6.5, platelets 22.[13][14]
This is severe falciparum malaria meeting five WHO severity criteria — cerebral malaria, hypoglycaemia, hyperparasitaemia, hyperlactataemia, and AKI — and the first drug he gets is IV artesunate, before the species is even confirmed. In reported ICU series, mortality has ranged from 8 to 30 per cent despite treatment, and every hour of delay costs lives.[10][13]
The spine of the topic hangs on three ideas: severe malaria is almost always falciparum, IV artesunate is first-line because it clears parasites faster and more safely than quinine, and the complications (cerebral oedema, hypoglycaemia, AKI, ARDS, blackwater fever, algid shock) are managed supportively while the artesunate works.[3][12]
References16ShowHide
- [1]Dondorp A, Nosten F, Stepniewska K, Day N, White N. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial Lancet, 2005.PMID 16125588
- [2]Dondorp AM, Fanello CI, Hendriksen IC, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial Lancet, 2010.PMID 21062666
- [3]White NJ, Pukrittayakamee S, Hien TT, et al. Malaria Lancet, 2014.PMID 23953767
- [4]Rosenthal PJ. Artesunate for the treatment of severe falciparum malaria N Engl J Med, 2008.PMID 18434652
- [5]Arguin PM Case definition: postartemisinin delayed hemolysis Blood, 2014.PMID 25013158
- [6]Riddle MS, Jackson JL, Sanders JW, Blazes DL. Exchange transfusion as an adjunct therapy in severe Plasmodium falciparum malaria: a meta-analysis Clin Infect Dis, 2002.PMID 11941545
- [7]Tan KR, Wiegand RE, Arguin PM. Exchange transfusion for severe malaria: evidence base and literature review Clin Infect Dis, 2013.PMID 23800940
- [8]Dondorp AM, Day NP The treatment of severe malaria Trans R Soc Trop Med Hyg, 2007.PMID 17434195
- [9]Schiess N, Villabona-Rueda A, Cottier KE, et al. Pathophysiology and neurologic sequelae of cerebral malaria Malar J, 2020.PMID 32703204
- [10]Karnad DR, Nor MBM, Richards GA, Baker T, Amin P. Intensive care in severe malaria: Report from the task force on tropical diseases by the World Federation of Societies of Intensive and Critical Care Medicine J Crit Care, 2018.PMID 29132978
- [11]Brejt JA, Golightly LM. Severe malaria: update on pathophysiology and treatment Curr Opin Infect Dis, 2019.PMID 31369419
- [12]Roussel C, Caumes E, Thellier M, Ndour PA, Buffet PA, Jauréguiberry S. Artesunate to treat severe malaria in travellers: review of efficacy and safety and practical implications J Travel Med, 2017.PMID 28395097
- [13]Santos LC, Abreu CF, Xerinda SM. Severe imported malaria in an intensive care unit: a review of 59 cases Malar J, 2012.PMID 22458840
- [14]Gaultier S, Houzé S, Thellier M. Prognosis of isolated hyperparasitemia in adults with imported severe malaria J Travel Med, 2025.PMID 40415188
- [15]Crawley J, Waruiru C, Mithwani S. Effect of phenobarbital on seizure frequency and mortality in childhood cerebral malaria: a randomised, controlled intervention study Lancet, 2000.PMID 10703801
- [16]Warrell DA, Looareesuwan S, Warrell MJ. Dexamethasone proves deleterious in cerebral malaria. A double-blind trial in 100 comatose patients N Engl J Med, 1982.PMID 7033788